We were very pleased with our choice to engage innoVitro’s contractility service. The studies using human iPSC-derived cardiomyocytes were tailored to our needs to provide results comparable to already existing (in house) data and the fast execution followed by a comprehensive study report completed the service perfectly.
Merck
- Post date August 20, 2020
News
- Cardiac Safety Committee Recognition Award 2022 -2023We are happy to announce innoVitro’s CTO Peter Linder has been awarded the HESI (Health and […]
- Meet us at the 2nd Microphysiological System World Summit in Berlin, Germany!The MPS conference will take place June 26 – 30, 2023 in the JW Marriott Hotel Berlin. Click […]
- innoVation Series December 22 / January 23With the New Year we are focussing on the importance of human iPSC-derived cardiomyocyte beat rate […]
